QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
TSE:BLU

BELLUS Health Stock Forecast, Price & News

C$5.07
+0.27 (+5.63 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.75
Now: C$5.07
C$5.15
50-Day Range
C$4.00
MA: C$4.78
C$5.74
52-Week Range
C$2.70
Now: C$5.07
C$16.68
Volume400,105 shs
Average Volume340,679 shs
Market CapitalizationC$397.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Headlines

LD Micro 360 Companies Set to Present this Week
August 31, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-6804500
Employees17
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$17,269.00
Price / Sales22,998.93
Cash FlowC$0.93 per share
Book ValueC$1.92 per share

Profitability

Miscellaneous

Market CapC$397.17 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$5.07
+0.27 (+5.63 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BELLUS Health (TSE:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health
or view top-rated stocks.

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for BELLUS Health
.

How has BELLUS Health's stock been impacted by Coronavirus (COVID-19)?

BELLUS Health's stock was trading at C$13.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLU stock has decreased by 61.0% and is now trading at C$5.07.
View which stocks have been most impacted by COVID-19
.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Mr. Roberto Francesco Bellini, Pres, CEO & Director (Age 41, Pay $661.99k)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 58, Pay $298.12k)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 64, Pay $469.3k)
  • Dr. Catherine M. Bonuccelli, Chief Medical Officer (Age 63, Pay $473.7k)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 48, Pay $304.5k)
  • Mr. Ramzi Benamar, Chief Financial Officer (Age 48)
  • Mr. Daniel Matthews, Director of Investor Relations & Communications
  • Mr. Sébastien Roy, Corp. Sec. (Age 45)

Who are some of BELLUS Health's key competitors?

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), The Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), The Boeing (BA) and The Walt Disney (DIS).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health?

Shares of BLU and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$5.07.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of C$397.17 million and generates C$17,269.00 in revenue each year.

How many employees does BELLUS Health have?

BELLUS Health employs 17 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.